Ambrisentan (Compound)

Synonyms:Ambrisentan, 177036-94-1, Letairis, Volibris, LU-208075, BSF 208075, BSF-208075, (S)-2-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid, LU 208075, (S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid, GSK1325760A, GSK-1325760A, HW6NV07QEC, GSK1325760, GSK-1325760, CHEMBL1111, DTXSID4046282, C22H22N2O4, (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid, Ambrisentan [INN], DTXCID2026282, LU208075, (s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid, CAS-177036-94-1, UNII-HW6NV07QEC, Ambrisentan [INN:BAN:JAN], NCGC00160662-01, Letairis (TN), Volibris (TN), Ambrisentan- Bio-X, BSF 208075;LU 208075, Ambrisentan (JAN/INN), AMBRISENTAN [MI], AMBRISENTAN [JAN], AMBRISENTAN [VANDF], SCHEMBL3679, AMBRISENTAN [MART.], AMBRISENTAN [WHO-DD], AMBRISENTAN, (+)-, MLS006010218, AMBRISENTAN [EMA EPAR], GTPL3951, AMBRISENTAN [ORANGE BOOK], CHEBI:135949, EX-A3315, Tox21_111967, BDBM50146710, FD7219, MFCD09842330, s2097, AKOS015994540, Tox21_111967_1, AC-9015, CCG-268386, CS-0447, DB06403, DE-0223, (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, NCGC00160662-02, NCGC00346730-01, BA164153, Benzenepropanoic acid, alpha-[(4,6-dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl-, (alphaS)-, HY-13209, SMR004701307, SW219060-1, D07077, AB01566890_01, EN300-7368573, Q410789, J-519579, (?S)-?-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-?-methoxy-?-phenylbenzenepropanoic acid, (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid, (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid, (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid

Pubchem:PUBCHEM:6918493

Id:65769d2f-3d77-5db3-96d1-cde87514edda

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Ambrisentan's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Ambrisentan.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Ambrisentan.

Results found

Linked to

	Label	Description
	BRD-K41185545-001-02-3 Substance (Entity type)	A Substance
	ambrisentan (b92dcd9c-e75e-43b7-a93f-836c1ef5aae0) Collection (Entity type)	Metadatata for ambrisentan
	DCSTRUCT ID 04337 Collection (Entity type)	DrugPage Collection: (DrugCentralID:04337; PubChem_CID:6918493, FILE=drugcentral_drug_04337.json)
	Ambrisentan negatively regulates MT1X Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan positively regulates IFRD2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan negatively regulates SCGB2A2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan positively regulates RNF167 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan in similarity relationship with CGP-12177 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan positively regulates TGFBI Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Ambrisentan positively regulates ANXA3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS